The Premier Gathering for the Life Science Anti-Corruption Community
The 19th Annual FCPA & Anti-Corruption for the Life Sciences Industry is the premier event for legal and compliance professionals from pharmaceutical, medical device, CRO, and biotechnology companies to connect, compare notes and expand their networks.
The 2024 program will stand apart, featuring practical, carefully researched content based on our key findings from multiple conversations with life sciences anti-corruption players. Our experts will probe only the most cutting-edge strategies and emerging trends.
Conference Co-Chairs
Marc Hennes
Head of Legal Investigations
Novartis
Rebecca Orttel
Vice President, Chief Ethics & Compliance Officer
Medtronic
Featured Speakers
Mike Stanek
Associate Vice President, Assistant General Counsel
Eli Lilly and Company
Claudius Sokenu
Executive Vice President, Chief Legal Officer, Chief Compliance and Regulatory Officer, and Corporate Secretary
Avantor
Drew Northern
Vice President, Chief Ethics & Compliance Officer
Cook Group and Cook Medical
Adam Yoffie
Executive Director, Head of C&E Investigations & Integrity Line
COMPANY
Natasha Trifun
Executive Director, Head of Compliance for EUCAN/International, R&D, and Operations
Alexion Pharmaceuticals
New For 2025
Join New Smaller-Group Third-Party Management Focus Groups: Navigating the Unique Corruption Risks of Third-Party Business Dealings in the Pharmaceutical, Biotech, CRO and Medical Device Contexts
Gain Proven Best Practices for Managing the Risks of Government-Run Healthcare Systems: Mitigating Corruption Exposures in Drug and Device Research, Testing and Approvals in Foreign Jurisdictions
Benefit from Actionable Takeaways for Doing Business in China: What It Takes to Thrive Amid the High-Risk Dynamics, New Healthcare Anti-Bribery Guidelines and Geopolitical Tensions
Participate in Hypothetical Exercises: What Would You Do If…? Tackling Complex Compliance Scenarios Involving the Use of Off-Channel Communications and Ephemeral Messaging
Business As Usual? Take Stock of the New Administration’s Impact on FCPA Enforcement and Compliance Expectations: To What Extent Life Sciences Companies Are Revisiting Their Risk Calculus and Programs-and How
Benefit from Practical Life Sciences-focused sessions on Brazil, India and Africa
Practical Implications of the Department of Justice’s M&A Safe Harbor Policy
On Oct. 4, 2023, Deputy Attorney General (DAG) Lisa Monaco announced a new Department of Justice policy intended to incentivize acquiring companies to voluntarily self-disclose criminal misconduct uncovered during a merger or acquisition. But it comes with a caveat that could have more of a chilling effect on
Benefit from 1:1, large and smaller-group networking and benchmarking with senior in-house decision-makers from pharmaceutical, biotech and medical device companies, and CROs! Compare notes, share “war stories” and hear lessons learned for mitigating heightened global compliance risks.
Join the go-to event of the year for the life sciences industry!
Accreditation
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.
Learn moreSponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Danny Maksad, Business Development Manager
Email: [email protected]
